Navigation Links
VIA Pharmaceuticals' Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Information's Therapeutic Area Partnerships Conference
Date:10/19/2007

- Company to be Featured on Oct 25, 2007 -

SAN FRANCISCO, Oct. 19 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP) a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Windhover Information has chosen the company's lead compound, VIA-2291, as one of the top ten most interesting cardiovascular projects available for partnering. VIA will be featured at Windhover Information's 2nd Annual Therapeutic Area Partnerships conference and Lawrence Cohen, Ph.D., chief executive officer and president of the company, will be providing more details about VIA-2291 at the meeting on October 25 at 2 p.m. Eastern Time in Philadelphia.

Windhover Information provides critical commentary, analysis and data to the biotech, pharmaceutical, and medical device and diagnostic industries. Its editorial and research staff, including the publishers of In Vivo and Startup, have chosen the top ten best compounds for licensing in each of four disease areas based on the following criteria: size of market, history of the molecule and drug, strength of the underlying science, diversity of potential indications, overall company strength and availability of multi-partnering opportunities.

"We are honored and delighted that VIA-2291 has been identified as one of the top cardiovascular drugs by the knowledgeable editorial and research staffs of the Windhover organization," said Dr. Cohen.

About VIA-2291

VIA's lead product candidate, VIA-2291, is a small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. VIA-2291 is a potent, selective and reversible inhibitor of 5-LO, which is a key enzyme in the biosynthesis of leukotrienes (important mediators of inflammation involved in the development and progression of atherosclerosis). VIA-2291 is being developed as a once-daily, oral drug to target inflammation in the blood vessel wall, thereby potentially decreasing the risk of major adverse cardiovascular events (MACE), including heart attack and stroke. According to the American Heart Association, 15.8 million patients in the U.S. have coronary artery disease.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase II clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

Forward-Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

* our ability to obtain necessary financing;

* our ability to control our operating expenses;

* our ability to recruit and enroll patients for the CEA, ACS and FDG-PET

clinical trials;

* our ability to successfully complete our clinical trials of VIA-2291 on

expected timetables and the outcomes of such clinical trials;

* the results of our clinical trials, including without limitation, with

respect to the safety and efficacy of VIA-2291;

* the outcome of any legal proceedings;

* our ability to obtain necessary FDA approvals;

* our ability to successfully commercialize VIA-2291;

* our ability to obtain and protect our intellectual property related to

our product candidates;

* our potential for future growth and the development of our product

pipeline;

* our ability to form and maintain collaborative relationships to develop

and commercialize our product candidates;

* general economic and business conditions; and

* the other risks described under the heading "Risk Factors" in our

Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 on

file with the SEC and in our Form S3 Amendment No. 3 filed with the SEC

October 15, 2007.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.


'/>"/>
SOURCE VIA Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Quintessence cancer treatment chosen for clinical studies
4. Evansville site chosen for biodiesel plant
5. Fiservs Banklink chosen by Union Bank of California
6. Detection of mRNAs on Cryosections of the Cardiovascular System Using DIG-Labeled RNA Probes
7. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
8. NY Medical Center Selects Camtronics for Cardiovascular Image and Information Management
9. 7 Programming
10. 7 Programming
11. 7 Programming
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
Breaking Biology Technology:
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):